Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track DVA with free AI briefings, catalyst countdowns, and dilution alerts.

DVA · DAVITA INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$604.7M Cash on Hand
CF+ Cash Runway
Follow DVA by email Get an email when DVA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about DVA, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Heparin Kidney Failure, Chronic Phase 3 · NCT02651428 Completed
Neutrolin Kidney Failure, Chronic Phase 3 · NCT02651428 Completed
Pentoxifylline Hypoalbuminemia Phase 3 · NCT00561093 Completed
FMX-8 Anemia of Chronic Disease Phase 2 · NCT01873534 Terminated
Thymalfasin COVID-19 Phase 2 · NCT04428008 Completed
Cavosonstat Drug Interaction Potentiation Phase 1 · NCT02500667 Completed
Nalbuphine Uremic Pruritus Phase 1 · NCT02373215 Completed

Also used in these trials (approved or third-party drugs, not DVA's own candidates): Calcium Acetate, Lanthanum Carbonate, Sevelamer Carbonate, Elbasvir And Grazoprevir, Rifampin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

DVA holds $604.7M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when DVA files for a raise →

👥 Who Owns DVA

Insiders 47.1% Other 5%+ holders 52.9% Institutions (864 holders) 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Warren E. Buffett 5%+ holder (13D) 35,892,479 57.06% 2025-02-11
BERKSHIRE HATHAWAY INC
10% owner
Insider 28,314,666 45.02% 2026-10-27
Javier Rodriguez
Chief Executive Officer, Director · +56,506 options
Insider 840,408 1.34% 2026-06-15
Joel Ackerman
CFO and Treasurer · +15,427 options
Insider 132,434 0.21% 2026-05-07
Kathleen Alyce Waters
Chief Legal & Pub. Affairs Off · +8,610 options
Insider 109,194 0.17% 2026-06-15
David Paul Maughan
Chief Operating Officer, DKC · +14,351 options
Insider 86,604 0.14% 2026-09-22
Pamela M Arway
Director
Insider 27,223 0.04% 2026-08-15
James O Hearty
Chief Compliance Officer · +3,050 options
Insider 22,389 0.04% 2026-05-14
Christopher Michael Berry
Chief Accounting Officer
Insider 19,640 0.03% 2026-03-15
Barbara J Desoer
Director
Insider 14,299 0.02% 2026-08-15
Phyllis R Yale
Director
Insider 9,803 0.02% 2026-08-15
Gregory J. Moore
Director
Insider 8,091 0.01% 2026-08-15

Share count 62,900,000 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full DVA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DVA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.